title: Favorable long-term outcome in adult genitourinary low-grade sarcoma.
abstract: OBJECTIVE
  To report our experience treating sarcomas in 20 consecutive patients.
  
  
  METHODS
  Pretreatment and follow-up data were obtained from 20 adult patients consecutively treated between 1992 and 1998 for primary or locally recurrent genitourinary sarcoma.
  
  
  RESULTS
  Eight patients (40%) were classified as having high-grade and 12 (60%) low-grade disease. Except for 3 patients, the primary treatment was surgery alone. The median follow-up was 52 months. The actuarial disease-specific 5-year survival rate was 84% in all patients and was 100% for patients with Memorial Sloan Kettering Cancer Center (MSKCC) Stages 1-2 and 54% in MSKCC Stages 3-4. The disease-specific survival was significantly better in low-grade tumors (log-rank test, P = 0.0063) and inguinal-scrotal tumors (P = 0.019), tumors 5 cm or less (P = 0.039), and MSKCC Stages 1-2 tumors (P = 0.0035).
  
  
  CONCLUSIONS
  The results of this study with a high proportion of low-grade, low-stage, and inguinal-scrotal sarcomas demonstrate the favorable prognosis of these subgroups.
authors.affiliation: Department of Urology, University Clinics Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Froehner
authors.forename: A
authors.initials: A
authors.lastname: Lossnitzer
authors.forename: A
authors.initials: A
authors.lastname: Manseck
authors.forename: R
authors.initials: R
authors.lastname: Koch
authors.forename: B
authors.initials: B
authors.lastname: Noack
authors.forename: M P
authors.initials: MP
authors.lastname: Wirth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005834:Genital Neoplasms, Male / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014565:Urogenital Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy